

Caroline Even

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11955086/caroline-even-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36
papers

4,602
citations

17
h-index

40
g-index

40
ext. papers

6,029
ext. citations

7.2
avg. IF

4.74
L-index

#	Paper	IF	Citations
36	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , 2022 , 2, 39-48		0
35	Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021 , 159, 125-132	7.5	0
34	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. <i>European Journal of Cancer</i> , 2021 , 158, 17-26	7.5	1
33	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPEXtreme): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 463-475	21.7	24
32	Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2021 , 112, 104984	4.4	0
31	Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait. <i>European Journal of Cancer</i> , 2021 , 145, 155-157	7.5	0
30	Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 6413-6423	12.9	11
29	Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2021 , 157, 190-197	7.5	1
28	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. <i>Radiotherapy and Oncology</i> , 2021 , 154, 125-127	5.3	4
27	Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). <i>European Journal of Cancer</i> , 2020 , 141, 21-29	7.5	20
26	Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy. <i>Laryngoscope</i> , 2020 , 130, E144-E150	3.6	2
25	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2019 , 121, 123-129	7.5	63
24	Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: Does response correlate with vocal cord mobility?. <i>Oral Oncology</i> , 2019 , 90, 13-16	4.4	2
23	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019 , 25, 5221-5230	12.9	74
22	New approaches in salivary gland carcinoma. <i>Current Opinion in Oncology</i> , 2019 , 31, 169-174	4.2	4
21	Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥5% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2019 , 107, 142-152	7.5	117
20	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 195-203	13.4	141

19	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018 , 81, 45-51	4.4	372
18	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018 , 3, e000257	6	40
17	Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?. <i>European Journal of Cancer</i> , 2018 , 94, 61-69	7.5	22
16	CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018 , 23, 1079-1082	5.7	44
15	High incidence of cetuximab-related infusion reactions in head and neck patients. <i>ESMO Open</i> , 2018 , 3, e000346	6	5
14	Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab. <i>Radiotherapy and Oncology</i> , 2018 , 128, 467-471	5.3	10
13	Relationship between the time to locoregional recurrence and survival in laryngeal squamous-cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017 , 274, 2267-2271	3.5	5
12	High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. <i>Cancer Discovery</i> , 2017 , 7, 586-595	24.4	347
11	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4050-4056	2.2	211
10	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1104-1115	21.7	232
9	Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy. <i>Laryngoscope</i> , 2017 , 127, 1791-1796	3.6	5
8	Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6024-6024	2.2	7
7	Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. <i>Oncotarget</i> , 2017 , 8, 51830-51839	3.3	2
6	Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016 , 62, 114-121	4.4	23
5	PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6086-6086	2.2	8
4	Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma. <i>Anticancer Research</i> , 2016 , 36, 6625-6630	2.3	9
3	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016 , 375, 1856-1867	59.2	2647
2	Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015 , 51, 742-50	7.5	70

- 1 Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study. *Haematologica*, **2011**, 96, 337-41 6.6 63